2023
Digital spatial profiling links beta-2-microglobulin expression with immune checkpoint blockade outcomes in head and neck squamous cell carcinoma
Gavrielatou N, Vathiotis I, Aung T, Shafi S, Burela S, Fernandez A, Moutafi M, Burtness B, Economopoulou P, Anastasiou M, Foukas P, Psyrri A, Rimm D. Digital spatial profiling links beta-2-microglobulin expression with immune checkpoint blockade outcomes in head and neck squamous cell carcinoma. Cancer Research Communications 2023, 3: 558-563. PMID: 37057033, PMCID: PMC10088911, DOI: 10.1158/2767-9764.crc-22-0299.Peer-Reviewed Original ResearchConceptsDigital spatial profilingB2M expressionOverall survivalM HNSCCImmunotherapy outcomesNeck squamous cell carcinoma (HNSCC) treatmentHigh beta-2 microglobulinSquamous cell carcinoma treatmentCell death protein 1Neck squamous cell carcinomaM expressionPretreatment biopsy samplesImmune checkpoint inhibitorsPD-L1 expressionImmune checkpoint markersDeath protein 1Squamous cell carcinomaB2MBeta-2-microglobulinBeta 2 microglobulin expressionImproved PFSCheckpoint inhibitorsMetastatic headCheckpoint markersImproved survival
2013
A Retrospective Population-Based Comparison of HER2 Immunohistochemistry and Fluorescence In Situ Hybridization in Breast Carcinomas: Impact of 2007 American Society of Clinical Oncology/ College of American Pathologists Criteria
Schalper KA, Kumar S, Hui P, Rimm DL, Gershkovich P. A Retrospective Population-Based Comparison of HER2 Immunohistochemistry and Fluorescence In Situ Hybridization in Breast Carcinomas: Impact of 2007 American Society of Clinical Oncology/ College of American Pathologists Criteria. Archives Of Pathology & Laboratory Medicine 2013, 138: 213-9. PMID: 24164555, DOI: 10.5858/arpa.2012-0617-oa.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBreast NeoplasmsCarcinomaCohort StudiesConnecticutFemaleHospitals, UniversityHumansImmunohistochemistryIn Situ Hybridization, FluorescenceMammary Glands, HumanMiddle AgedNeoplasm GradingNeoplasm InvasivenessNeoplasm ProteinsPractice Guidelines as TopicReceptor, ErbB-2Retrospective StudiesSocieties, MedicalUnited StatesUnited States Food and Drug Administration
2011
Comparative Prognostic Value of Epidermal Growth Factor Quantitative Protein Expression Compared with FISH for Head and Neck Squamous Cell Carcinoma
Pectasides E, Rampias T, Kountourakis P, Sasaki C, Kowalski D, Fountzilas G, Zaramboukas T, Rimm D, Burtness B, Psyrri A. Comparative Prognostic Value of Epidermal Growth Factor Quantitative Protein Expression Compared with FISH for Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research 2011, 17: 2947-2954. PMID: 21355076, DOI: 10.1158/1078-0432.ccr-10-2040.Peer-Reviewed Original ResearchCarcinomaCarcinoma, Squamous CellEpidermal Growth FactorFemaleGene DosageGene Expression Regulation, NeoplasticHead and Neck NeoplasmsHumansIn Situ Hybridization, FluorescenceMaleNeoplasms, Squamous CellPredictive Value of TestsPrognosisProteinsSquamous Cell Carcinoma of Head and NeckSurvival AnalysisTissue Array Analysis
2006
Construction and Validation of Tissue Microarrays of Ductal Carcinoma In Situ and Terminal Duct Lobular Units Associated With Invasive Breast Carcinoma
Yang XR, Charette LA, Garcia-Closas M, Lissowska J, Paal E, Sidawy M, Hewitt SM, Rimm DL, Sherman ME. Construction and Validation of Tissue Microarrays of Ductal Carcinoma In Situ and Terminal Duct Lobular Units Associated With Invasive Breast Carcinoma. Applied Immunohistochemistry & Molecular Morphology 2006, 15: 157-161. PMID: 16932071, DOI: 10.1097/01.pdm.0000213453.45398.e0.Peer-Reviewed Original ResearchConceptsTerminal duct lobular unitsTissue microarrayEstrogen receptorDuctal carcinomaProgesterone receptorBreast cancerLobular unitsLarge case-control studyPR expression levelsCase-control studyInvasive breast carcinomaPercentage of tubulesInvasive carcinomaEpithelial lesionsBreast carcinomaImmunohistochemical characterizationImmunohistochemical stainingPeritumoral tissuesPositive stainingScoring systemCarcinomaCategorical scoring systemBreast tissueMethodologic studyExpression levelsMet, the Hepatocyte Growth Factor Receptor, Localizes to the Nucleus in Cells at Low Density
Pozner-Moulis S, Pappas DJ, Rimm DL. Met, the Hepatocyte Growth Factor Receptor, Localizes to the Nucleus in Cells at Low Density. Cancer Research 2006, 66: 7976-7982. PMID: 16912172, DOI: 10.1158/0008-5472.can-05-4335.Peer-Reviewed Original Research
2005
Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients with Epithelial Ovarian Cancer
Psyrri A, Kassar M, Yu Z, Bamias A, Weinberger PM, Markakis S, Kowalski D, Camp RL, Rimm DL, Dimopoulos MA. Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients with Epithelial Ovarian Cancer. Clinical Cancer Research 2005, 11: 8637-8643. PMID: 16361548, DOI: 10.1158/1078-0432.ccr-05-1436.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptorOvarian cancerOverall survivalPrognostic valuePlatinum-paclitaxel combination chemotherapyAdvanced stage ovarian cancerDisease-free survivalSignificant prognostic factorsAdverse prognostic indicatorEpithelial ovarian cancerTumor EGFR expressionEGFR expression statusImportant prognostic informationConflicting resultsEpidermal growth factor receptor expression levelsEGFR protein expressionReceptor expression levelsGrowth factor receptorSurgical debulkingCombination chemotherapyPrognostic factorsMultivariable analysisEntire cohortPoor outcomePrognostic indicator
2004
αB‐crystallin as a marker of lymph node involvement in breast carcinoma
Chelouche‐Lev D, Kluger HM, Berger AJ, Rimm DL, Price JE. αB‐crystallin as a marker of lymph node involvement in breast carcinoma. Cancer 2004, 100: 2543-2548. PMID: 15197794, DOI: 10.1002/cncr.20304.Peer-Reviewed Original ResearchConceptsLymph node involvementBreast carcinoma cell linesBreast carcinomaNode involvementCarcinoma cell linesHuman breast carcinoma cell lineLymph node negative breast carcinomaPrimary breast carcinoma specimensLymph node positive breast carcinomaNode-positive breast carcinomaNode-negative breast carcinomaCell linesAdvanced breast carcinomaLymph node statusPredictors of survivalAlphaB-crystallinClinical prognostic markersLymph node metastasisHigh nuclear gradePrimary breast carcinomaBreast carcinoma specimensNovel tumor markerHuman breast carcinomaAlphaB-crystallin expressionIntensity of expressionMolecular markers for prognosis after isolated postmastectomy chest wall recurrence
Haffty BG, Hauser A, Choi DH, Parisot N, Rimm D, King B, Carter D. Molecular markers for prognosis after isolated postmastectomy chest wall recurrence. Cancer 2004, 100: 252-263. PMID: 14716758, DOI: 10.1002/cncr.11915.Peer-Reviewed Original ResearchConceptsHER-2/neu statusChest wall recurrencePositive HER-2/neu statusLocal-regional controlLocal recurrenceNeu statusDistant metastasisPR statusProgesterone receptorBreast carcinomaDistant metastasis-free survival ratesLocal chest wall recurrenceDistant metastasis-free rateMetastasis-free survival ratesHER-2/neuLymph node recurrencePositive PR statusProgression-free rateSimultaneous distant metastasesOperable breast carcinomaLocal-regional recurrenceMetastasis-free ratePostmastectomy chest wallExternal beam radiotherapyLong-term survival
2001
Use of magnetic enrichment for detection of carcinoma cells in fluid specimens
Kielhorn E, Schofield K, Rimm DL. Use of magnetic enrichment for detection of carcinoma cells in fluid specimens. Cancer 2001, 94: 205-211. PMID: 11815978, DOI: 10.1002/cncr.10193.Peer-Reviewed Original ResearchConceptsFluid specimensEpithelial cellsCarcinoma cellsCell enrichmentDetection of malignancyDetermination of malignancyRare epithelial cellsE-cadherin stainingPleural effusionAccurate stagingMetastatic carcinomaCytologic evaluationCytologic diagnosisMedical conditionsAtypical casesMalignant casesMalignant cellsInsufficient cellsNegative casesImmunomagnetic enrichmentAscites fluidMalignancyImmunomagnetic selectionCommon eventβ-Catenin Dysregulation in Thyroid Neoplasms Down-Regulation, Aberrant Nuclear Expression, and CTNNB1 Exon 3 Mutations Are Markers for Aggressive Tumor Phenotypes and Poor Prognosis
Garcia-Rostan G, Camp R, Herrero A, Carcangiu M, Rimm D, Tallini G. β-Catenin Dysregulation in Thyroid Neoplasms Down-Regulation, Aberrant Nuclear Expression, and CTNNB1 Exon 3 Mutations Are Markers for Aggressive Tumor Phenotypes and Poor Prognosis. American Journal Of Pathology 2001, 158: 987-996. PMID: 11238046, PMCID: PMC1850336, DOI: 10.1016/s0002-9440(10)64045-x.Peer-Reviewed Original ResearchMeSH KeywordsAdenomaAdultAgedBeta CateninBiomarkers, TumorCarcinomaCell DivisionCell NucleusCytoskeletal ProteinsDown-RegulationExonsFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedOncogene Protein p21(ras)PhenotypePoint MutationPolymorphism, Single-Stranded ConformationalPrognosisSurvival RateThyroid NeoplasmsTrans-ActivatorsConceptsPoor prognosisTumor differentiationBeta-catenin expressionConventional prognostic indicatorsAggressive tumor phenotypeNuclear beta-catenin localizationThyroid tumor samplesBeta-catenin dysregulationAberrant nuclear expressionΒ-catenin dysregulationDifferentiated tumorsPrognostic indicatorThyroid cancerThyroid neoplasmsNuclear immunoreactivityBeta-catenin alterationsNuclear expressionTumor samplesProgressive lossCarcinomaTumor phenotypeSingle-strand conformational polymorphismBeta-catenin mutationsHuman cancersDown regulationDiagnosis of “ASCUS” in women over age 50 is less likely to be associated with dysplasia
Flynn K, Rimm D. Diagnosis of “ASCUS” in women over age 50 is less likely to be associated with dysplasia. Diagnostic Cytopathology 2001, 24: 132-136. PMID: 11169895, DOI: 10.1002/1097-0339(200102)24:2<132::aid-dc1026>3.0.co;2-n.Peer-Reviewed Original Research
2000
E‐cadherin expression is a sensitive and specific method for detection of carcinoma cells in fluid specimens
Schofield K, D'Aquila T, Rimm D. E‐cadherin expression is a sensitive and specific method for detection of carcinoma cells in fluid specimens. Diagnostic Cytopathology 2000, 22: 263-267. PMID: 10790230, DOI: 10.1002/(sici)1097-0339(200005)22:5<263::aid-dc1>3.0.co;2-4.Peer-Reviewed Original Research
1999
Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma
Camp R, Rimm E, Rimm D. Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 1999, 86: 2259-2265. PMID: 10590366, DOI: 10.1002/(sici)1097-0142(19991201)86:11<2259::aid-cncr13>3.0.co;2-2.Peer-Reviewed Original ResearchConceptsAxillary lymph node negative breast carcinomaLymph node negative breast carcinomaExpression of METNode-negative breast carcinomaNegative breast carcinomaBreast carcinomaMET expressionMetastatic diseaseRelative riskNegative invasive ductal carcinomaLow Met expressionMET-negative patientsIndependent predictive valueIndependent prognostic markerUseful prognostic indicatorInvasive ductal carcinomaStandard immunoperoxidase techniqueHigh MET expressionHepatocyte growth factorActivation of METAxillary lymphNegative patientsPatient agePrognostic factorsAggressive diseaseFrequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma.
Garcia-Rostan G, Tallini G, Herrero A, D'Aquila TG, Carcangiu ML, Rimm DL. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Research 1999, 59: 1811-5. PMID: 10213482.Peer-Reviewed Original ResearchConceptsNuclear localizationSingle-strand conformational polymorphismE-cadherin-mediated cell-cell adhesionBeta-catenin actsFrequent nuclear localizationCell-cell adhesionExon 3Conformational polymorphismBeta-catenin genePhosphorylation sitesWingless pathwayTranscriptional activationCytoplasmic proteinsSubcellular localizationMobility shiftMutational analysisNucleotide sequencingDNA sequencingNuclear translocationSomatic alterationsMutationsAnaplastic thyroid carcinomaSequencingProteinFrequent mutations
1995
Reduced alpha-catenin and E-cadherin expression in breast cancer.
Rimm DL, Sinard JH, Morrow JS. Reduced alpha-catenin and E-cadherin expression in breast cancer. Laboratory Investigation 1995, 72: 506-12. PMID: 7745946.Peer-Reviewed Original ResearchConceptsE-cadherinSteady-state levelsE-cadherin expressionHomotypic cell adhesion proteinMetastatic diseaseCell adhesion proteinsHuman E-cadherinCell-cell interactionsCytoplasmic proteinsTime of biopsyAdhesion proteinsAggressive tumor behaviorAdhesive functionEffector elementsAdhesion cascadeAbsent E-cadherin expressionTypes of cancerJunctional complexesProteinBreast cancerEpithelial tumorsSensitive markerTumor behaviorExpressionCancer